Rigel Pharmaceuticals | RIGL - Gross Profit On Sales


Rigel Pharmaceuticals reported $28.49M in Gross Profit on Sales for its fiscal quarter ending in June of 2024.





Gross Profit On Sales Change Date
Agenus USD 34.2M 4.61M Dec/2025
Amgen USD 6.48B 307M Sep/2025
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
AstraZeneca USD 12.39B 5M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Celldex Therapeutics USD 121K 609K Dec/2025
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Intrexon USD -297K 167K Jun/2024
Ionis Pharmaceuticals USD 195M 40M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
MacroGenics USD 31.11M 30.14M Dec/2025
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Sangamo BioSciences -2.39M 1.09M Jun/2024
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Veracyte USD 101.97M 10.69M Dec/2025